Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
OG-L002 (OG-L-002) is a pecific inhibitor of LSD-1 [ lysine (K)-specific demethylase 1A] with potential antiviral activity. It inhibits LSD-1 with an IC50 of 20 nM in a cell-free assay, and displays 36- and 69-fold selectivity for LSD-1 over MAO-B and MAO-A, respectively. OG-L002 shows potent in vitro antiviral activity and high in vivo efficacy. It was foud to inhibit herpes simplex virus (HSV) immediate early gene expression and viral yield in vitro and suppresses HSV primary infection in vivo.
ln Vitro |
In comparison to the control MAOI TCP (IC50: ~1 mM), OG-L002 greatly reduces the IE gene expression of the virus in both cells (IC50: ~10 µM in HeLa cells and ~3 µM in HFF cells)[1].
|
---|---|
ln Vivo |
In the ganglia, OG-L002 (ip; 6–40 mg/kg; daily; for 7 days) decreases detectable viral genome levels in a dose-dependent manner at 3 and 5 days after infection[1].
|
Animal Protocol |
Animal/Disease Models: 4 weeks old BALB/c female mice[1]
Doses: 6, 20, 40 mg/kg Route of Administration: Intraperitoneal; daily; for 7 days Experimental Results: decreased the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection. |
References |
[1]. Liang Y, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12.
|
Molecular Formula |
C15H15NO
|
---|---|
Molecular Weight |
225.29
|
CAS # |
1357302-64-7
|
SMILES |
OC1=CC(C2=CC=C([C@@H]3[C@@H](N)C3)C=C2)=CC=C1
|
InChi Key |
DSOJSZXQRJGBCW-CABCVRRESA-N
|
InChi Code |
InChI=1S/C15H15NO/c16-15-9-14(15)11-6-4-10(5-7-11)12-2-1-3-13(17)8-12/h1-8,14-15,17H,9,16H2/t14-,15+/m1/s1
|
Chemical Name |
4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol
|
Synonyms |
OGL002; OGL 002; OG-L002
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.4387 mL | 22.1936 mL | 44.3872 mL | |
5 mM | 0.8877 mL | 4.4387 mL | 8.8774 mL | |
10 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.